FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2277082935> ?p ?o ?g. }

• W2277082935 endingPage "678" @default.
• W2277082935 startingPage "673" @default.
• W2277082935 abstract "A phase I study with topotecan (SKF 104864-A, NSC 609699), a semisynthetic analog of camptothecin, was performed using a daily-times-5 regimen, given i.v. q 3 weeks, to evaluate the pharmacokinetics and toxicities of the compound.Patients with a histologically confirmed diagnosis of a solid tumor no longer amenable to established forms of treatment were eligible for the study. Topotecan was given as a 30 min. infusion daily on 5 successive days, repeated every three weeks. In subsequent patient cohorts the dose was escalated from 0.5 to 1.5 mg/m2/day. Weekly evaluations included hematology and biochemistry. Response to treatment was assessed every 2 cycles. Pharmacokinetics were performed using a HPLC method.Forty-eight patients were entered. The maximal tolerated dose was 1.5 mg/m2/day. The dose limiting toxicity was leucocytopenia. Other major toxicities were alopecia and moderate nausea/vomiting. Partial remissions were observed in one patient with pretreated small-cell lung cancer, one with non-small-cell lung cancer and one with no-pretreated pancreatic cancer, lasting 130-240 days. Pharmacokinetics showed a t 1/2 (alpha) of 8.1 +/- 7.6 min., t 1/2 (beta) of 132 +/- 48 min., Vd,ss 72.7 +/- 26.9 L/m2 and Cltot of 0.57 +/- 0.16 L/min/m2.Topotecan is an interesting new topoisomerase I inhibitor exerting antitumor activity in this phase I trial. Leucocytopenia is dose-limiting. The recommended dose for phase II studies is 1.5 mg/m2/day for 5 consecutive days every 3 weeks." @default.
• W2277082935 created "2016-06-24" @default.
• W2277082935 creator A5000286751 @default.
• W2277082935 creator A5002058325 @default.
• W2277082935 creator A5005190279 @default.
• W2277082935 creator A5011819733 @default.
• W2277082935 creator A5013575185 @default.
• W2277082935 creator A5041259777 @default.
• W2277082935 creator A5045167907 @default.
• W2277082935 creator A5062227574 @default.
• W2277082935 date "1993-09-01" @default.
• W2277082935 modified "2023-10-02" @default.
• W2277082935 title "Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor" @default.
• W2277082935 cites W1536538430 @default.
• W2277082935 cites W1952453258 @default.
• W2277082935 cites W1997361520 @default.
• W2277082935 cites W2023174165 @default.
• W2277082935 cites W2063892537 @default.
• W2277082935 cites W2066206601 @default.
• W2277082935 cites W2078751203 @default.
• W2277082935 cites W2145189913 @default.
• W2277082935 cites W2175445951 @default.
• W2277082935 doi "https://doi.org/10.1093/oxfordjournals.annonc.a058623" @default.
• W2277082935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8240998" @default.
• W2277082935 hasPublicationYear "1993" @default.
• W2277082935 type Work @default.
• W2277082935 sameAs 2277082935 @default.
• W2277082935 citedByCount "114" @default.
• W2277082935 countsByYear W22770829352013 @default.
• W2277082935 countsByYear W22770829352016 @default.
• W2277082935 countsByYear W22770829352021 @default.
• W2277082935 crossrefType "journal-article" @default.
• W2277082935 hasAuthorship W2277082935A5000286751 @default.
• W2277082935 hasAuthorship W2277082935A5002058325 @default.
• W2277082935 hasAuthorship W2277082935A5005190279 @default.
• W2277082935 hasAuthorship W2277082935A5011819733 @default.
• W2277082935 hasAuthorship W2277082935A5013575185 @default.
• W2277082935 hasAuthorship W2277082935A5041259777 @default.
• W2277082935 hasAuthorship W2277082935A5045167907 @default.
• W2277082935 hasAuthorship W2277082935A5062227574 @default.
• W2277082935 hasBestOaLocation W22770829351 @default.
• W2277082935 hasConcept C112705442 @default.
• W2277082935 hasConcept C126322002 @default.
• W2277082935 hasConcept C147897179 @default.
• W2277082935 hasConcept C178790620 @default.
• W2277082935 hasConcept C181199279 @default.
• W2277082935 hasConcept C185592680 @default.
• W2277082935 hasConcept C2776256026 @default.
• W2277082935 hasConcept C2776694085 @default.
• W2277082935 hasConcept C2779682216 @default.
• W2277082935 hasConcept C2780580376 @default.
• W2277082935 hasConcept C2780852908 @default.
• W2277082935 hasConcept C2781209748 @default.
• W2277082935 hasConcept C2781413609 @default.
• W2277082935 hasConcept C29730261 @default.
• W2277082935 hasConcept C31760486 @default.
• W2277082935 hasConcept C55493867 @default.
• W2277082935 hasConcept C71924100 @default.
• W2277082935 hasConcept C90924648 @default.
• W2277082935 hasConcept C98274493 @default.
• W2277082935 hasConceptScore W2277082935C112705442 @default.
• W2277082935 hasConceptScore W2277082935C126322002 @default.
• W2277082935 hasConceptScore W2277082935C147897179 @default.
• W2277082935 hasConceptScore W2277082935C178790620 @default.
• W2277082935 hasConceptScore W2277082935C181199279 @default.
• W2277082935 hasConceptScore W2277082935C185592680 @default.
• W2277082935 hasConceptScore W2277082935C2776256026 @default.
• W2277082935 hasConceptScore W2277082935C2776694085 @default.
• W2277082935 hasConceptScore W2277082935C2779682216 @default.
• W2277082935 hasConceptScore W2277082935C2780580376 @default.
• W2277082935 hasConceptScore W2277082935C2780852908 @default.
• W2277082935 hasConceptScore W2277082935C2781209748 @default.
• W2277082935 hasConceptScore W2277082935C2781413609 @default.
• W2277082935 hasConceptScore W2277082935C29730261 @default.
• W2277082935 hasConceptScore W2277082935C31760486 @default.
• W2277082935 hasConceptScore W2277082935C55493867 @default.
• W2277082935 hasConceptScore W2277082935C71924100 @default.
• W2277082935 hasConceptScore W2277082935C90924648 @default.
• W2277082935 hasConceptScore W2277082935C98274493 @default.
• W2277082935 hasIssue "8" @default.
• W2277082935 hasLocation W22770829351 @default.
• W2277082935 hasLocation W22770829352 @default.
• W2277082935 hasOpenAccess W2277082935 @default.
• W2277082935 hasPrimaryLocation W22770829351 @default.
• W2277082935 hasRelatedWork W1582941957 @default.
• W2277082935 hasRelatedWork W1841552349 @default.
• W2277082935 hasRelatedWork W1896363289 @default.
• W2277082935 hasRelatedWork W1992222388 @default.
• W2277082935 hasRelatedWork W207057374 @default.
• W2277082935 hasRelatedWork W2070716213 @default.
• W2277082935 hasRelatedWork W2243955004 @default.
• W2277082935 hasRelatedWork W2277082935 @default.
• W2277082935 hasRelatedWork W2407451361 @default.
• W2277082935 hasRelatedWork W2414579301 @default.
• W2277082935 hasVolume "4" @default.
• W2277082935 isParatext "false" @default.
• W2277082935 isRetracted "false" @default.
• W2277082935 magId "2277082935" @default.

• next